Journal of cutaneous pathology · 2025
Primary Cutaneous Peripheral T-Cell Lymphoma With Follicular Helper T-Cell Phenotype.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Planella-Fontanillas Nidia, Molina-Alvarez Andrea, Colomo-Saperas Lluís, Rovira Roger, Gonzàlez-Farré Monica, Barranco-Sanz Carlos, Calvo Xavier, Nadal-Pellisé Clara, Gallardo Fernando, Pujol Ramon M
Аннотация
An otherwise healthy 82-year-old woman presented with recurrent, asymptomatic erythematous papulo-nodular lesions on the face and extremities. A skin biopsy revealed a dense, non-epidermotropic lymphohistiocytic infiltrate with granulomatous features and a mixed population of medium-sized atypical lymphoid cells and plasma cells. Immunohistochemistry demonstrated a predominant CD4+ T-cell population with a T-follicular helper (TFH) phenotype (PD1+, CXCL13+, BCL6+), admixed with EBV-negative monotypic B-cells. Clonality was confirmed for both T and B cells by BIOMED2 PCR, and a RHOA p.G17V mutation was identified. Next-generation sequencing revealed additional mutations in TET2 and DNMT3A. Complete staging studies showed no nodal or visceral involvement. A minimal circulating population (0.11%) of atypical CD4+ T-cells with surface CD3 loss and TFH markers was detected in peripheral blood. Based on clinical and histopathological findings, a diagnosis of primary cutaneous peripheral T-cell lymphoma with TFH phenotype (pcPTCL-TFH) was made. The patient also developed a cutaneous squamous cell carcinoma, in which a peritumoral TFH lymphoid infiltrate with the same clonal features was identified. This case illustrates the diagnostic complexity of pcPTCL-TFH and its potential overlap with systemic TFH-derived lymphomas, underscoring the need for molecular work-up and close clinical follow-up to detect possible extracutaneous progression.